XORTX Therapeutics Initiates Reverse Stock Split to Maintain Exchange Listings

XORTX Therapeutics is taking decisive action to address regulatory pressures. The biotechnology firm will implement a 1-for-5 reverse stock split this coming Monday, April 6. This move, approved by relevant regulators, is a strategic effort to secure the company’s continued listing on both the Nasdaq and the TSX.

A Strategic Consolidation to Meet Listing Standards

The primary driver for this corporate action is the requirement to maintain a minimum share price, a common condition for continued Nasdaq listing. By consolidating shares, XORTX aims to correct its optically low trading price to comply with these ongoing regulatory mandates.

Upon execution, the number of outstanding shares will be reduced from approximately 6.96 million to about 1.39 million. While the per-share price will increase proportionally, the total market value of shareholders’ investments will remain unchanged. This structural reset is designed to provide the technical foundation for the company’s future on public exchanges.

Should investors sell immediately? Or is it worth buying XORTX Therapeutics?

Financial Health and Clinical Pipeline Focus

Despite this financial engineering, XORTX’s fundamental challenges persist. For the 2025 fiscal year, the company reported a net loss of USD 2.66 million. Its accumulated deficit has now grown to over USD 23.8 million. As of early April 2026, its market capitalization reflected a range between USD 2.74 million and CAD 4.38 million, depending on the exchange.

The company’s long-term valuation prospects remain firmly tied to the progress of its clinical development programs. XORTX continues to channel its operational focus into three key therapeutic candidates:
* XRx-008: A treatment targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD).
* XRx-026: A clinical program focused on therapies for gout.
* XRx-101: A candidate being developed for Acute Kidney Injury.

The success of these trials, rather than the reverse split, will ultimately be the critical factor for the company’s future performance and investor appeal.